BMS-5

• Description:

  BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.

• Product Name Alternative:

  LIMKi 3

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  LIM Kinase (LIMK)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMS-5.html

• Concentration:

  10mM

• Purity:

  99.84

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)C(NC1=NC=C(C2=CC(C(F)F)=NN2C3=C(Cl)C=CC=C3Cl)S1)=O

• Molecular Formula:

  C17H14Cl2F2N4OS

• Molecular Weight:

  431.29

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7 (11) :3490-8.|[2]Petrilli A, et al. LIM Domain Kinases as Potential Therapeutic Targets for Neurofibromatosis Type 2.Oncogene. Oncogene. 2014 Jul 3;33 (27) :3571-82.|[3]Lunardi P, et al. Effects of Hippocampal LIMK Inhibition on Memory Acquisition, Consolidation, Retrieval, Reconsolidation, and Extinction. Mol Neurobiol. 2017 Jan 13.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  LIMK1; LIMK2

• CAS Number:

  [1338247-35-0]